Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study
Background Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC. Metho...
Saved in:
| Published in | International journal of clinical oncology Vol. 21; no. 4; pp. 676 - 683 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Tokyo
Springer Japan
01.08.2016
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1341-9625 1437-7772 |
| DOI | 10.1007/s10147-015-0942-0 |
Cover
| Abstract | Background
Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC.
Methods
Pegylated interferon α-2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period.
Results
The subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively (
p
= 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study.
Conclusions
The results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. |
|---|---|
| AbstractList | Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC.
Pegylated interferon α-2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period.
The subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively (p = 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study.
The results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. Background Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC. Methods Pegylated interferon α-2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period. Results The subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively ( p = 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study. Conclusions The results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. Background Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC. Methods Pegylated interferon [alpha]-2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period. Results The subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively (p = 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study. Conclusions The results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC. Pegylated interferon alpha -2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period. The subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively (p = 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study. The results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. BACKGROUNDSorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for HCC. To clarify the efficacy, combination therapy with sorafenib and interferon was performed for patients with advanced HCC.METHODSPegylated interferon α-2a was administered every 2 weeks for the initial 4 weeks. Subsequently, it was combined with sorafenib. We evaluated the anti-tumor effect and biomarkers during treatment period.RESULTSThe subjects were 13 patients with advanced HCC complicated by hepatitis C virus (HCV)-related liver cirrhosis. A partial response, stable disease and progressive disease were noted in 4, 6, and 3 patients, respectively. The response rate, the disease control rate, the mean time to progression and the median survival time (MST) were 30.8 % (4/13), 76.9 % (10/13), 12.2 months, and 17.5 months, respectively. In 8 Child-Pugh class A and 5 Child-Pugh class B patients, the MST was 22.0 and 11.0 months, respectively (p = 0.001). In plasma vascular endothelial growth factor (VEGF), serum alpha-fetoprotein (AFP), AFP-L3, a protein induced by vitamin K absence or antagonist-II (PIVKA II), and hepatocyte growth factor (HGF), there was no pretreatment factor and no biomarker during the combination therapy to predict therapeutic effect in the present study.CONCLUSIONSThe results of this study suggest that combination therapy with sorafenib and interferon could be effective and safe in advanced HCC patients with HCV-related liver cirrhosis. |
| Author | Atsukawa, Masanori Itokawa, Norio Nakagawa, Ai Kondo, Chisa Tsubota, Akihito Okubo, Tomomi Iwakiri, Katsuhiko Arai, Taeang |
| Author_xml | – sequence: 1 givenname: Norio surname: Itokawa fullname: Itokawa, Norio organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital – sequence: 2 givenname: Masanori surname: Atsukawa fullname: Atsukawa, Masanori email: momogachi@yahoo.co.jp organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital – sequence: 3 givenname: Akihito surname: Tsubota fullname: Tsubota, Akihito organization: Core Research Facilities for Basic Science, Research Center for Medical Sciences, Jikei University, School of Medicine – sequence: 4 givenname: Tomomi surname: Okubo fullname: Okubo, Tomomi organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital – sequence: 5 givenname: Taeang surname: Arai fullname: Arai, Taeang organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital – sequence: 6 givenname: Ai surname: Nakagawa fullname: Nakagawa, Ai organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital – sequence: 7 givenname: Chisa surname: Kondo fullname: Kondo, Chisa organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital – sequence: 8 givenname: Katsuhiko surname: Iwakiri fullname: Iwakiri, Katsuhiko organization: Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26701173$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtv1TAQhS1URB_wA9ggS2zYBGYc39hhh6rykCqxgH3ka4-5rhI72A7V_ffN5RaEKoFYzSy-c-ZxztlJTJEYe47wGgHUm4KAUjWAmwZ6KRp4xM5QtqpRSomTtW8lNn0nNqfsvJQbAFTdRjxhp6JTgKjaM1auvCdbC0-el5SNpxi23KZpGyI5fhvqjo_ptnGpEA-xUvaUU-R1R9nMe-5T5sb9MNGu9I5mU5OlcVxGk7k12YaYJvOWGz6HMVVe6uL2T9ljb8ZCz-7rBfvy_urr5cfm-vOHT5fvrhsrRV-bXqHopfZSWumxVxJ0C9aCRuO6Hhxiq9B3RKCp30q30YTagDPGi9a1F-zV0XXO6ftCpQ5TKIfdTKS0lAE1otadVPgf6DpaYy_0ir58gN6kJcf1jJ-G0EoNsFIv7qllO5Eb5hwmk_fDr7-vAB4Bm1MpmfxvBGE4ZDscsx3WbIdDtsPBVD3Q2FBNDSnWbML4T6U4Kss6JX6j_MfSfxXdAaFRty8 |
| CitedBy_id | crossref_primary_10_1038_s41392_020_00264_x crossref_primary_10_3389_fcell_2023_1156383 crossref_primary_10_1038_s41598_017_12414_3 |
| Cites_doi | 10.1016/j.canlet.2009.09.009 10.1016/j.juro.2010.07.033 10.1093/jnci/95.6.437 10.1053/j.gastro.2007.04.061 10.1159/000082097 10.2174/138945011794815301 10.1002/hep.20933 10.1200/JCO.2007.10.8613 10.1200/JCO.2007.11.1047 10.1097/MEG.0b013e32835d913b 10.1016/j.bbrc.2012.05.056 10.1016/S0140-6736(08)61033-8 10.1007/s10147-010-0151-9 10.1056/NEJMoa0708857 10.1159/000082098 10.7326/0003-4819-131-3-199908030-00003 10.1200/JCO.2012.48.4410 10.1159/000327577 10.1016/j.ejca.2008.10.026 10.1016/S0140-6736(00)03595-9 10.1200/JCO.2013.54.3298 10.1016/j.eururo.2012.08.027 10.2220/biomedres.29.271 10.1002/hep.510290624 10.1080/02841850801958890 10.1158/1078-0432.CCR-11-2175 10.1016/j.cgh.2009.10.026 10.1016/j.jhep.2011.12.001 10.1002/hep.510290439 10.1016/j.ejca.2009.10.013 10.1007/s00535-013-0853-7 10.1159/000334454 10.1200/JCO.2012.45.8372 10.1016/S0140-6736(03)14964-1 10.1055/s-0030-1247132 10.1016/S1470-2045(08)70285-7 10.1073/pnas.91.4.1198 10.1111/ijcp.12352 10.1016/j.jhep.2012.02.016 10.1002/hep.24199 10.1002/cncr.28384 10.3892/ijo.2013.1904 10.1200/JCO.1999.17.9.2859 |
| ContentType | Journal Article |
| Copyright | Japan Society of Clinical Oncology 2015 Japan Society of Clinical Oncology 2016 |
| Copyright_xml | – notice: Japan Society of Clinical Oncology 2015 – notice: Japan Society of Clinical Oncology 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9. M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1007/s10147-015-0942-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Research Library Prep Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1437-7772 |
| EndPage | 683 |
| ExternalDocumentID | 4145691741 26701173 10_1007_s10147_015_0942_0 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29J 29~ 2J2 2JN 2JY 2KG 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACUDM ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ~A9 ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PUEGO CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c429t-9712948f44c4f19740830cc081ad690d11371f6ee08e9b4d58e18a0daaf23d3 |
| IEDL.DBID | U2A |
| ISSN | 1341-9625 |
| IngestDate | Thu Sep 04 17:51:35 EDT 2025 Thu Oct 02 12:09:26 EDT 2025 Tue Oct 07 05:16:59 EDT 2025 Wed Feb 19 02:00:16 EST 2025 Thu Apr 24 23:01:17 EDT 2025 Wed Oct 01 02:30:06 EDT 2025 Fri Feb 21 02:33:40 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Hepatocellular carcinoma α-Fetoprotein Pegylated interferon Vascular endothelial growth factor Sorafenib |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c429t-9712948f44c4f19740830cc081ad690d11371f6ee08e9b4d58e18a0daaf23d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 26701173 |
| PQID | 1811034800 |
| PQPubID | 43390 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1811886471 proquest_miscellaneous_1808381928 proquest_journals_1811034800 pubmed_primary_26701173 crossref_primary_10_1007_s10147_015_0942_0 crossref_citationtrail_10_1007_s10147_015_0942_0 springer_journals_10_1007_s10147_015_0942_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20160800 2016-8-00 2016-Aug 20160801 |
| PublicationDateYYYYMMDD | 2016-08-01 |
| PublicationDate_xml | – month: 8 year: 2016 text: 20160800 |
| PublicationDecade | 2010 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Japan |
| PublicationTitle | International journal of clinical oncology |
| PublicationTitleAbbrev | Int J Clin Oncol |
| PublicationTitleAlternate | Int J Clin Oncol |
| PublicationYear | 2016 |
| Publisher | Springer Japan Springer Nature B.V |
| Publisher_xml | – name: Springer Japan – name: Springer Nature B.V |
| References | (CR3) 2012; 56 Nishiguchi, Shiomi, Nakatani (CR16) 2001; 357 Llovet, Ricci, Mazzaferro (CR4) 2008; 359 Bracarda, Eggermont, Samuelsson (CR13) 2010; 46 Lencioni, Llovet (CR25) 2010; 30 Cheng, Kang, Lin (CR8) 2013; 31 Kasai, Ushio, Kasai (CR31) 2011; 16 Ikeda, Saitoh, Arase (CR15) 1999; 29 Kudo, Izumi, Kokudo (CR23) 2010; 29 Tochizawa, Masumori, Yanai (CR35) 2008; 29 Gutterman (CR12) 1994; 91 Singal, Singh, Jaganmohan (CR17) 2010; 8 Gollob, Rathmell, Richmond (CR19) 2007; 25 Bruix, Sherman (CR24) 2011; 53 Bracarda, Porta, Boni (CR34) 2013; 63 Wang, Xu, Gao (CR43) 2008; 49 Kuzuya, Asahina, Tsuchiya (CR39) 2011; 81 Yoshida, Shiratori, Moriyama (CR18) 1999; 131 Llovet, Pena, Lathia (CR41) 2012; 18 Kusano, Ogasawara, Akiba (CR22) 2013; 42 Personeni, Bozzarelli, Pressiani (CR38) 2012; 57 Pyrhonen, Salminen, Ruutu (CR26) 1999; 1 Ryan, Goldman, Lara (CR20) 2007; 25 Lencioni, Kudo, Ye (CR7) 2014; 68 von Marschall, Scholz, Cramer (CR14) 2003; 95 Yano, Iemura, Haramaki (CR29) 1999; 29 Tsuchiya, Asahina, Matsuda (CR42) 2014; 120 Takeuchi, Eto, Tatsugami (CR36) 2010; 184 Cheng, Kang, Chen (CR5) 2009; 10 Nishiguchi, Tamori, Kubo (CR32) 2005; 48 Bruix, Sherman (CR1) 2005; 42 Zhang, Sun, Zhou (CR30) 2010; 290 Ikeda, Mitsunaga, Shimizu (CR6) 2014; 49 Johnson, Qin, Park (CR9) 2013; 31 Simonsson, Hjorth-Hansen, Bjerrum (CR28) 2011; 12 Eisenhauer, Therasse, Bogaerts (CR37) 2009; 45 Sakaguchi, Kudo, Fukunaga (CR33) 2005; 48 Llovet, Burroughs, Bruix (CR2) 2003; 362 Eggermont, Suciu, Santinami (CR27) 2008; 372 Nakazawa, Hidaka, Takada (CR40) 2013; 25 El-Serag, Rudolph (CR11) 2007; 132 Cainap, Qin, Huang (CR10) 2015; 33 Wang, Jia, Duan (CR21) 2012; 422 S Nishiguchi (942_CR16) 2001; 357 JM Llovet (942_CR2) 2003; 362 S Tochizawa (942_CR35) 2008; 29 S Pyrhonen (942_CR26) 1999; 1 EA Eisenhauer (942_CR37) 2009; 45 K Tsuchiya (942_CR42) 2014; 120 PJ Johnson (942_CR9) 2013; 31 S Bracarda (942_CR13) 2010; 46 L Wang (942_CR21) 2012; 422 AK Singal (942_CR17) 2010; 8 JM Llovet (942_CR4) 2008; 359 JU Gutterman (942_CR12) 1994; 91 N Personeni (942_CR38) 2012; 57 AL Cheng (942_CR8) 2013; 31 European Association For The Study Of The Liver1, European Organisation For Research And Treatment Of Cancer (942_CR3) 2012; 56 C Cainap (942_CR10) 2015; 33 B Simonsson (942_CR28) 2011; 12 H Yoshida (942_CR18) 1999; 131 R Lencioni (942_CR7) 2014; 68 T Zhang (942_CR30) 2010; 290 K Kasai (942_CR31) 2011; 16 AM Eggermont (942_CR27) 2008; 372 H Yano (942_CR29) 1999; 29 CW Ryan (942_CR20) 2007; 25 J Bruix (942_CR1) 2005; 42 T Nakazawa (942_CR40) 2013; 25 K Ikeda (942_CR15) 1999; 29 T Kuzuya (942_CR39) 2011; 81 AL Cheng (942_CR5) 2009; 10 S Bracarda (942_CR34) 2013; 63 M Ikeda (942_CR6) 2014; 49 J Bruix (942_CR24) 2011; 53 Y Sakaguchi (942_CR33) 2005; 48 HB El-Serag (942_CR11) 2007; 132 R Lencioni (942_CR25) 2010; 30 A Takeuchi (942_CR36) 2010; 184 M Kudo (942_CR23) 2010; 29 S Nishiguchi (942_CR32) 2005; 48 JA Gollob (942_CR19) 2007; 25 H Kusano (942_CR22) 2013; 42 JM Llovet (942_CR41) 2012; 18 B Wang (942_CR43) 2008; 49 Z Marschall von (942_CR14) 2003; 95 22374331 - Clin Cancer Res. 2012 Apr 15;18(8):2290-300 19822391 - Cancer Lett. 2010 Apr 28;290(2):204-10 21132451 - Int J Clin Oncol. 2011 Jun;16(3):221-9 23395995 - Eur J Gastroenterol Hepatol. 2013 Jun;25(6):683-9 23588838 - Int J Oncol. 2013 Jun;42(6):1897-903 22414760 - J Hepatol. 2012 Jul;57(1):101-7 18568538 - Acta Radiol. 2008 Jun;49(5):523-9 12644537 - J Natl Cancer Inst. 2003 Mar 19;95(6):437-48 22116493 - Oncology. 2011;81(3-4):251-8 21829027 - Dig Dis. 2011;29(3):339-64 11213099 - Lancet. 2001 Jan 20;357(9251):196-7 24283303 - Int J Clin Pract. 2014 May;68(5):609-17 24081937 - J Clin Oncol. 2013 Nov 10;31(32):4067-75 19129670 - Biomed Res. 2008 Dec;29(6):271-8 17664477 - J Clin Oncol. 2007 Aug 1;25(22):3296-301 18650514 - N Engl J Med. 2008 Jul 24;359(4):378-90 22964169 - Eur Urol. 2013 Feb;63(2):254-61 15785092 - Intervirology. 2005;48(1):64-70 24122122 - Cancer. 2014 Jan 15;120(2):229-37 22634008 - Biochem Biophys Res Commun. 2012 Jun 15;422(4):687-92 21374666 - Hepatology. 2011 Mar;53(3):1020-2 18620949 - Lancet. 2008 Jul 12;372(9633):117-26 23793266 - J Gastroenterol. 2014 May;49(5):932-40 14667750 - Lancet. 2003 Dec 6;362(9399):1907-17 10094956 - Hepatology. 1999 Apr;29(4):1124-30 15785093 - Intervirology. 2005;48(1):71-5 19095497 - Lancet Oncol. 2009 Jan;10(1):25-34 10347112 - Hepatology. 1999 Jun;29(6):1708-17 17664476 - J Clin Oncol. 2007 Aug 1;25(22):3288-95 19906524 - Eur J Cancer. 2010 Jan;46(2):284-97 16250051 - Hepatology. 2005 Nov;42(5):1208-36 23980084 - J Clin Oncol. 2013 Oct 1;31(28):3517-24 21143150 - Curr Drug Targets. 2011 Mar 1;12(3):420-8 25488963 - J Clin Oncol. 2015 Jan 10;33(2):172-9 17570226 - Gastroenterology. 2007 Jun;132(7):2557-76 22424438 - J Hepatol. 2012 Apr;56(4):908-43 10428733 - Ann Intern Med. 1999 Aug 3;131(3):174-81 20175033 - Semin Liver Dis. 2010 Feb;30(1):52-60 8108387 - Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 19879972 - Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9 21030044 - J Urol. 2010 Dec;184(6):2549-56 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 10561363 - J Clin Oncol. 1999 Sep;17 (9):2859-67 |
| References_xml | – volume: 290 start-page: 204 year: 2010 end-page: 210 ident: CR30 article-title: Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells publication-title: Cancer Lett doi: 10.1016/j.canlet.2009.09.009 – volume: 184 start-page: 2549 year: 2010 end-page: 2556 ident: CR36 article-title: Mechanism of synergistic antitumor effect of sorafenib and interferon-alpha on treatment of renal cell carcinoma publication-title: J Urol doi: 10.1016/j.juro.2010.07.033 – volume: 95 start-page: 437 year: 2003 end-page: 448 ident: CR14 article-title: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis publication-title: J Natl Cancer Inst doi: 10.1093/jnci/95.6.437 – volume: 132 start-page: 2557 year: 2007 end-page: 2576 ident: CR11 article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.061 – volume: 48 start-page: 64 year: 2005 end-page: 70 ident: CR33 article-title: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma publication-title: Intervirology doi: 10.1159/000082097 – volume: 42 start-page: 1897 year: 2013 end-page: 1903 ident: CR22 article-title: Antiproliferative effects of sorafenib and pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo publication-title: Int J Oncol – volume: 12 start-page: 420 year: 2011 end-page: 428 ident: CR28 article-title: Interferon alpha for treatment of chronic myeloid leukemia publication-title: Curr Drug Targets doi: 10.2174/138945011794815301 – volume: 42 start-page: 1208 year: 2005 end-page: 1236 ident: CR1 article-title: Management of hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 25 start-page: 3288 year: 2007 end-page: 3295 ident: CR19 article-title: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.10.8613 – volume: 25 start-page: 3296 year: 2007 end-page: 3301 ident: CR20 article-title: Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.1047 – volume: 25 start-page: 683 year: 2013 end-page: 689 ident: CR40 article-title: Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32835d913b – volume: 422 start-page: 687 year: 2012 end-page: 692 ident: CR21 article-title: Combined anti-tumor effects of IFN-alpha and sorafenib on hepatocellular carcinoma in vitro and in vivo publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2012.05.056 – volume: 372 start-page: 117 year: 2008 end-page: 126 ident: CR27 article-title: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial publication-title: Lancet doi: 10.1016/S0140-6736(08)61033-8 – volume: 16 start-page: 221 year: 2011 end-page: 229 ident: CR31 article-title: Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma publication-title: Int J Clin Oncol doi: 10.1007/s10147-010-0151-9 – volume: 359 start-page: 378 year: 2008 end-page: 390 ident: CR4 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – volume: 48 start-page: 71 year: 2005 end-page: 75 ident: CR32 article-title: Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma publication-title: Intervirology doi: 10.1159/000082098 – volume: 131 start-page: 174 year: 1999 end-page: 181 ident: CR18 article-title: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy publication-title: Ann Intern Med doi: 10.7326/0003-4819-131-3-199908030-00003 – volume: 31 start-page: 3517 year: 2013 end-page: 3524 ident: CR9 article-title: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study publication-title: J Clin Oncol doi: 10.1200/JCO.2012.48.4410 – volume: 29 start-page: 339 year: 2010 end-page: 364 ident: CR23 article-title: Management of hepatocellular carcinoma in Japan: consensus-based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version publication-title: Dig Dis doi: 10.1159/000327577 – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: CR37 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 357 start-page: 196 year: 2001 end-page: 197 ident: CR16 article-title: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis publication-title: Lancet doi: 10.1016/S0140-6736(00)03595-9 – volume: 33 start-page: 172 year: 2015 end-page: 179 ident: CR10 article-title: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2013.54.3298 – volume: 63 start-page: 254 year: 2013 end-page: 261 ident: CR34 article-title: Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY) publication-title: Eur Urol doi: 10.1016/j.eururo.2012.08.027 – volume: 29 start-page: 271 year: 2008 end-page: 278 ident: CR35 article-title: Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines publication-title: Biomed Res doi: 10.2220/biomedres.29.271 – volume: 29 start-page: 1708 year: 1999 end-page: 1717 ident: CR29 article-title: Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines publication-title: Hepatology doi: 10.1002/hep.510290624 – volume: 49 start-page: 523 year: 2008 end-page: 529 ident: CR43 article-title: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization publication-title: Acta Radiol doi: 10.1080/02841850801958890 – volume: 18 start-page: 2290 year: 2012 end-page: 2300 ident: CR41 article-title: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2175 – volume: 1 start-page: 2859 issue: 7 year: 1999 end-page: 2867 ident: CR26 article-title: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer publication-title: J Clin Onco – volume: 8 start-page: 192 year: 2010 end-page: 199 ident: CR17 article-title: Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.10.026 – volume: 56 start-page: 908 year: 2012 end-page: 943 ident: CR3 article-title: EASL-EORTC clinical practice guidelines management of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2011.12.001 – volume: 29 start-page: 1124 year: 1999 end-page: 1130 ident: CR15 article-title: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis publication-title: Hepatology doi: 10.1002/hep.510290439 – volume: 46 start-page: 284 year: 2010 end-page: 297 ident: CR13 article-title: Redefining the role of interferon in the treatment of malignant diseases publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.10.013 – volume: 49 start-page: 932 year: 2014 end-page: 940 ident: CR6 article-title: Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization publication-title: J Gastroenterol doi: 10.1007/s00535-013-0853-7 – volume: 81 start-page: 251 year: 2011 end-page: 258 ident: CR39 article-title: Early decrease in alpha-fetoprotein, but not des-gamma-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma publication-title: Oncology doi: 10.1159/000334454 – volume: 31 start-page: 4067 year: 2013 end-page: 4075 ident: CR8 article-title: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.8372 – volume: 362 start-page: 1907 year: 2003 end-page: 1917 ident: CR2 article-title: Hepatocellular carcinoma publication-title: Lancet doi: 10.1016/S0140-6736(03)14964-1 – volume: 30 start-page: 52 year: 2010 end-page: 60 ident: CR25 article-title: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma publication-title: Semin Liver Dis doi: 10.1055/s-0030-1247132 – volume: 10 start-page: 25 year: 2009 end-page: 34 ident: CR5 article-title: Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70285-7 – volume: 91 start-page: 1198 year: 1994 end-page: 1205 ident: CR12 article-title: Cytokine therapeutics: lessons from interferon alpha publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.91.4.1198 – volume: 68 start-page: 609 year: 2014 end-page: 617 ident: CR7 article-title: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis publication-title: Int J Clin Pract doi: 10.1111/ijcp.12352 – volume: 57 start-page: 101 year: 2012 end-page: 107 ident: CR38 article-title: Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2012.02.016 – volume: 53 start-page: 1020 year: 2011 end-page: 1022 ident: CR24 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology doi: 10.1002/hep.24199 – volume: 120 start-page: 229 year: 2014 end-page: 237 ident: CR42 article-title: Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma publication-title: Cancer doi: 10.1002/cncr.28384 – volume: 357 start-page: 196 year: 2001 ident: 942_CR16 publication-title: Lancet doi: 10.1016/S0140-6736(00)03595-9 – volume: 46 start-page: 284 year: 2010 ident: 942_CR13 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.10.013 – volume: 30 start-page: 52 year: 2010 ident: 942_CR25 publication-title: Semin Liver Dis doi: 10.1055/s-0030-1247132 – volume: 372 start-page: 117 year: 2008 ident: 942_CR27 publication-title: Lancet doi: 10.1016/S0140-6736(08)61033-8 – volume: 49 start-page: 523 year: 2008 ident: 942_CR43 publication-title: Acta Radiol doi: 10.1080/02841850801958890 – volume: 68 start-page: 609 year: 2014 ident: 942_CR7 publication-title: Int J Clin Pract doi: 10.1111/ijcp.12352 – volume: 31 start-page: 3517 year: 2013 ident: 942_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.48.4410 – volume: 16 start-page: 221 year: 2011 ident: 942_CR31 publication-title: Int J Clin Oncol doi: 10.1007/s10147-010-0151-9 – volume: 63 start-page: 254 year: 2013 ident: 942_CR34 publication-title: Eur Urol doi: 10.1016/j.eururo.2012.08.027 – volume: 42 start-page: 1897 year: 2013 ident: 942_CR22 publication-title: Int J Oncol doi: 10.3892/ijo.2013.1904 – volume: 120 start-page: 229 year: 2014 ident: 942_CR42 publication-title: Cancer doi: 10.1002/cncr.28384 – volume: 18 start-page: 2290 year: 2012 ident: 942_CR41 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2175 – volume: 8 start-page: 192 year: 2010 ident: 942_CR17 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.10.026 – volume: 422 start-page: 687 year: 2012 ident: 942_CR21 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2012.05.056 – volume: 56 start-page: 908 year: 2012 ident: 942_CR3 publication-title: J Hepatol doi: 10.1016/j.jhep.2011.12.001 – volume: 91 start-page: 1198 year: 1994 ident: 942_CR12 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.91.4.1198 – volume: 53 start-page: 1020 year: 2011 ident: 942_CR24 publication-title: Hepatology doi: 10.1002/hep.24199 – volume: 42 start-page: 1208 year: 2005 ident: 942_CR1 publication-title: Hepatology doi: 10.1002/hep.20933 – volume: 359 start-page: 378 year: 2008 ident: 942_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – volume: 25 start-page: 3288 year: 2007 ident: 942_CR19 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.10.8613 – volume: 57 start-page: 101 year: 2012 ident: 942_CR38 publication-title: J Hepatol doi: 10.1016/j.jhep.2012.02.016 – volume: 10 start-page: 25 year: 2009 ident: 942_CR5 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70285-7 – volume: 25 start-page: 3296 year: 2007 ident: 942_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.1047 – volume: 132 start-page: 2557 year: 2007 ident: 942_CR11 publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.061 – volume: 25 start-page: 683 year: 2013 ident: 942_CR40 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32835d913b – volume: 131 start-page: 174 year: 1999 ident: 942_CR18 publication-title: Ann Intern Med doi: 10.7326/0003-4819-131-3-199908030-00003 – volume: 31 start-page: 4067 year: 2013 ident: 942_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.8372 – volume: 12 start-page: 420 year: 2011 ident: 942_CR28 publication-title: Curr Drug Targets doi: 10.2174/138945011794815301 – volume: 29 start-page: 1708 year: 1999 ident: 942_CR29 publication-title: Hepatology doi: 10.1002/hep.510290624 – volume: 45 start-page: 228 year: 2009 ident: 942_CR37 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 362 start-page: 1907 year: 2003 ident: 942_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(03)14964-1 – volume: 29 start-page: 1124 year: 1999 ident: 942_CR15 publication-title: Hepatology doi: 10.1002/hep.510290439 – volume: 29 start-page: 339 year: 2010 ident: 942_CR23 publication-title: Dig Dis doi: 10.1159/000327577 – volume: 49 start-page: 932 year: 2014 ident: 942_CR6 publication-title: J Gastroenterol doi: 10.1007/s00535-013-0853-7 – volume: 290 start-page: 204 year: 2010 ident: 942_CR30 publication-title: Cancer Lett doi: 10.1016/j.canlet.2009.09.009 – volume: 48 start-page: 71 year: 2005 ident: 942_CR32 publication-title: Intervirology doi: 10.1159/000082098 – volume: 95 start-page: 437 year: 2003 ident: 942_CR14 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/95.6.437 – volume: 48 start-page: 64 year: 2005 ident: 942_CR33 publication-title: Intervirology doi: 10.1159/000082097 – volume: 1 start-page: 2859 issue: 7 year: 1999 ident: 942_CR26 publication-title: J Clin Onco doi: 10.1200/JCO.1999.17.9.2859 – volume: 33 start-page: 172 year: 2015 ident: 942_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.54.3298 – volume: 184 start-page: 2549 year: 2010 ident: 942_CR36 publication-title: J Urol doi: 10.1016/j.juro.2010.07.033 – volume: 81 start-page: 251 year: 2011 ident: 942_CR39 publication-title: Oncology doi: 10.1159/000334454 – volume: 29 start-page: 271 year: 2008 ident: 942_CR35 publication-title: Biomed Res doi: 10.2220/biomedres.29.271 – reference: 23793266 - J Gastroenterol. 2014 May;49(5):932-40 – reference: 17664477 - J Clin Oncol. 2007 Aug 1;25(22):3296-301 – reference: 24081937 - J Clin Oncol. 2013 Nov 10;31(32):4067-75 – reference: 20175033 - Semin Liver Dis. 2010 Feb;30(1):52-60 – reference: 24283303 - Int J Clin Pract. 2014 May;68(5):609-17 – reference: 19822391 - Cancer Lett. 2010 Apr 28;290(2):204-10 – reference: 11213099 - Lancet. 2001 Jan 20;357(9251):196-7 – reference: 23395995 - Eur J Gastroenterol Hepatol. 2013 Jun;25(6):683-9 – reference: 24122122 - Cancer. 2014 Jan 15;120(2):229-37 – reference: 15785093 - Intervirology. 2005;48(1):71-5 – reference: 19906524 - Eur J Cancer. 2010 Jan;46(2):284-97 – reference: 19129670 - Biomed Res. 2008 Dec;29(6):271-8 – reference: 18620949 - Lancet. 2008 Jul 12;372(9633):117-26 – reference: 22414760 - J Hepatol. 2012 Jul;57(1):101-7 – reference: 23588838 - Int J Oncol. 2013 Jun;42(6):1897-903 – reference: 21143150 - Curr Drug Targets. 2011 Mar 1;12(3):420-8 – reference: 18650514 - N Engl J Med. 2008 Jul 24;359(4):378-90 – reference: 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 – reference: 23980084 - J Clin Oncol. 2013 Oct 1;31(28):3517-24 – reference: 22424438 - J Hepatol. 2012 Apr;56(4):908-43 – reference: 10094956 - Hepatology. 1999 Apr;29(4):1124-30 – reference: 19095497 - Lancet Oncol. 2009 Jan;10(1):25-34 – reference: 21829027 - Dig Dis. 2011;29(3):339-64 – reference: 21132451 - Int J Clin Oncol. 2011 Jun;16(3):221-9 – reference: 17664476 - J Clin Oncol. 2007 Aug 1;25(22):3288-95 – reference: 21030044 - J Urol. 2010 Dec;184(6):2549-56 – reference: 15785092 - Intervirology. 2005;48(1):64-70 – reference: 19879972 - Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9 – reference: 22374331 - Clin Cancer Res. 2012 Apr 15;18(8):2290-300 – reference: 12644537 - J Natl Cancer Inst. 2003 Mar 19;95(6):437-48 – reference: 14667750 - Lancet. 2003 Dec 6;362(9399):1907-17 – reference: 10561363 - J Clin Oncol. 1999 Sep;17 (9):2859-67 – reference: 21374666 - Hepatology. 2011 Mar;53(3):1020-2 – reference: 10428733 - Ann Intern Med. 1999 Aug 3;131(3):174-81 – reference: 17570226 - Gastroenterology. 2007 Jun;132(7):2557-76 – reference: 22634008 - Biochem Biophys Res Commun. 2012 Jun 15;422(4):687-92 – reference: 10347112 - Hepatology. 1999 Jun;29(6):1708-17 – reference: 22116493 - Oncology. 2011;81(3-4):251-8 – reference: 8108387 - Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 – reference: 16250051 - Hepatology. 2005 Nov;42(5):1208-36 – reference: 18568538 - Acta Radiol. 2008 Jun;49(5):523-9 – reference: 25488963 - J Clin Oncol. 2015 Jan 10;33(2):172-9 – reference: 22964169 - Eur Urol. 2013 Feb;63(2):254-61 |
| SSID | ssj0017652 |
| Score | 2.1041296 |
| Snippet | Background
Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and... Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and interferon for... Background Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and... BACKGROUNDSorafenib is a standard of care for advanced hepatocellular carcinoma (HCC). An in vitro study showed the synergistic effects of sorafenib and... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 676 |
| SubjectTerms | Aged Aged, 80 and over alpha-Fetoproteins - metabolism Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers - blood Biomarkers, Tumor - blood Cancer Research Cancer therapies Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Disease Progression Female Hepatitis C, Chronic - complications Hepatocyte Growth Factor - blood Humans Interferon-alpha - administration & dosage Liver cancer Liver Cirrhosis - complications Liver Cirrhosis - virology Liver Neoplasms - complications Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Niacinamide - administration & dosage Niacinamide - analogs & derivatives Oncology Original Article Phenylurea Compounds - administration & dosage Pilot Projects Polyethylene Glycols - administration & dosage Protein Precursors - blood Proteins Prothrombin Recombinant Proteins - administration & dosage Studies Surgical Oncology Survival Rate Vascular Endothelial Growth Factor A - blood |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9UwEB7WsyC-iHe7rhLBJyWYtmnaCiIquyzCHsQL7FvJFReOzdnTLuK_d6aXs8rieW2TMs0kmW8yk28AXvjCZ8GJmptaVFzm3nGjQsGlzfCJqmszVJ47XaqT7_LTWXG2B8v5LgylVc574rBRu2jpjPw1WqJU5BLxzbv1BaeqURRdnUto6Km0gns7UIzdgP2MmLEWsP_haPn5yzauUKqhBg-xmPEaof8c5xwv06WS0jALji5PxsW_luoa_LwWOh0s0vEduD1BSfZ-1P1d2PPtPbh5OgXL70M3MhN3LAbWoaaDb88Nw79FZ9g7RiewbBV_cRc7z4g2YhP8JrZsvJL1myGcZXOKAPuBZquPdMxPeavMUgmiNv7Ub5hm6_NV7NlAVPsAvh4ffft4wqcaC9yiJep5XaLBl1WQ0sqQonOBkExYi0BBO3ScXZrmZRqU96LytZGuqHxaaeG0Dlnu8oewaGPrHwPLpXB5ZlJtyoKoRY3LJPayylqHHwsJiHk0GzvRj1MVjFVzRZxMCmhQAQ0poBEJvNx2WY_cG7saH84qaqZl2DVXkyaB59vXuIBouHTr4yW1wV8mWrhqVxv0wyqFhjyBR6P6txJlqiRevTyBV_N8-EuA_4l7sFvcJ3ALkZkaMw0PYdFvLv1TRD-9eTZN6T-cJP_k priority: 102 providerName: ProQuest |
| Title | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study |
| URI | https://link.springer.com/article/10.1007/s10147-015-0942-0 https://www.ncbi.nlm.nih.gov/pubmed/26701173 https://www.proquest.com/docview/1811034800 https://www.proquest.com/docview/1808381928 https://www.proquest.com/docview/1811886471 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1437-7772 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1437-7772 dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: 7X7 dateStart: 19970301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1437-7772 dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: BENPR dateStart: 19970301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1437-7772 dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: 8C1 dateStart: 19970301 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1437-7772 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1437-7772 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS90wFD9sCmMv4uY-6twlwp4cgaRN03ZvV7lOFGXohLun0nwx4drIbUX23--kH3cON8GXFtqkJDlJz-_knPwOwCeb2tgZVlBVsJyKxBqqpEup0DE-kUWhusxzp2fy6FIcz9P5cI67GaPdR5dk96e-d9iNixAmmVI0SWKKdvp6Gti8cBJfxtOV6yCTXZqdQFRGC0T3oyvzX5_4Wxk9QJgPvKOd0jnchI0BLZJpL95X8MzWr-HF6eAP34KmJx9uiHekQWE6W18pgv1Be9caEjZZycLfUeMbSwIzxNLZpa9Jf-rqF0HESsYoAPITNVPrw05-CE0lOmQZqv119YVU5OZq4VvScdG-gYvD2feDIzqkUaAalU1Liwx1usidEFo4jvYDoi6mNWKByqBtbDhPMu6ktSy3hRImzS3PK2aqysWJSd7CWu1r-x5IIphJYsUrlaWBPVSZWGAtLbU2-DEXARtHs9QDw3hIdLEo_3AjBwGUKIAyCKBkEeytqtz09BqPFd4ZRVQOK60pEaFwlgjEvRHsrl7jGgnDVdXW34Yy2OXA_JY_VgZNrVyiro7gXS_-VYtimQXqvCSCz-N8uNeA_zV3-0mlP8BLxGKyjy3cgbV2eWs_It5p1QSeZ_MMr_kBn8D69OuPkxne92dn384n3dz_DdIn-tI |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VVgJeKm7SFjASvIAsnMS5kCrE0WpLuysEReoTUeJDVNrG202qqv-tP46ZHFtQxb71NbEjxzP2fOMZfwPwykQmsFpkvMxEymVoNC9jG3GpAnwSZ1nZVp4bT-LRT_n1KDpagcvhLgylVQ57YrtRa6fojPwdWiJfhBLxzYfZKaeqURRdHUpoFH1pBb3dUoz1Fzv2zcU5unD19t4XlPfrINjdOfw84n2VAa5wL254lqDJk6mVUknrI7xGUCKUQlNZaHQdte-HiW9jY0RqslLqKDV-WghdFDYIdYhfvQVrMpQZun5rn3Ym374vohhJ3Fb8Ic40nqGjMURVu6t7vqSkz4ijgxVw8a9dvAZ2rwVqW_u3ew_We-DKPnaadh9WTPUAbo_70PxDqDse5Jo5y2rUK2uq45Lh3KLrbTSj8142dedcu9owIqmYWzN3FesugF0wBM9sSEhgv9FINo6CCpQlyxQVPKrcSfGeFWx2PHUNa2lxH8GPG5jrx7Bauco8BRZKocOg9IsyiYjItNSBxF4qVkrjx6wHYpjNXPVk51RzY5pf0TSTAHIUQE4CyIUHbxZdZh3Tx7LGW4OI8n7R1_mVinrwcvEalytNV1EZd0Zt8JeJhC5d1ga9vjRG2ODBk078ixEFcUIsfqEHbwd9-GsA_xvuxvLhvoA7o8PxQX6wN9nfhLuICeMux3ELVpv5mXmGuKspn_fqzeDXza6nP722OsU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB5qheJL8d5oqyvoi7J0k93chCJiPbTWFkGF82RI9kILx-zxJKX0n_nznMnlVCmet74mu2GzM7vzzc7sNwAvbWwjZ0TOq1xkXElreJW4mCsd4ZMkz6uu8tzxSXLwXX2axtM1-D3ehaG0ynFP7DZq4zWdke-iJQqFVIhvdt2QFvFlf_Ju_otTBSmKtI7lNHoVObKXF-i-NXuH-yjrV1E0-fjtwwEfKgxwjftwy_MUzZ3KnFJauRChNQISoTWaydKg22jCUKahS6wVmc0rZeLMhlkpTFm6SBqJX70Ft1Mpc0omTKdLVy9Mk67WD7Gl8RxdjDGe2l_aCxWle8YcXauIi38t4jWYey1E21m-yV3YHCAre9_r2D1Ys_V92DgegvIPoOkZkBvmHWtQo5ytzyqGs4pOtzWMTnrZzF9w4xvLiJ5i4ezC16y_-nXJEDazMRWBnaJ5bD2FEyg_lmkqdVT7n-VbVrL52cy3rCPEfQhfb2CmH8F67Wu7BUwqYWRUhWWVxkRhWplIYS-daG3wYy4AMc5moQeac6q2MSuuCJpJAAUKoCABFCKA18su857jY1Xj7VFExbDcm-JKOQN4sXyNC5Wmq6ytP6c2-MtEP5etaoP-XpYgYAjgcS_-5YiiJCX-PhnAm1Ef_hrA_4b7ZPVwn8MGrqLi8-HJ0VO4g2Aw6ZMbt2G9XZzbHQRcbfWs020GP252Kf0BDU44Xw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+sorafenib+combined+with+low-dose+interferon+therapy+for+advanced+hepatocellular+carcinoma%3A+a+pilot+study&rft.jtitle=International+journal+of+clinical+oncology&rft.au=Itokawa%2C+Norio&rft.au=Atsukawa%2C+Masanori&rft.au=Tsubota%2C+Akihito&rft.au=Okubo%2C+Tomomi&rft.date=2016-08-01&rft.pub=Springer+Japan&rft.issn=1341-9625&rft.eissn=1437-7772&rft.volume=21&rft.issue=4&rft.spage=676&rft.epage=683&rft_id=info:doi/10.1007%2Fs10147-015-0942-0&rft.externalDocID=10_1007_s10147_015_0942_0 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-9625&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-9625&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-9625&client=summon |